FIELD: medicine.
SUBSTANCE: invention aims to predict a response to a routine two-component antiretroviral therapy in patients with chronic hepatitis C (CHC) genotype 1B. To predict the reliability of the response to the routine two-component antiretroviral therapy with pegylated interferons and ribavirin in patients with chronic hepatitis C genotype 1B, a genetic blood test is conducted to analyse IL28B gene polymorphism and specify a blood group. A stable virological response in 100% of the time is predicted in the patients with 0αβ (I) blood group and IL28B gene polymorphism rs12979860 in genotype C/C and rs8099917 in genotype T/T. A stable virological response in 80% of the time is predicted in the patients with Aβ (II) blood group and a one-nucleotide cytosine substitution by thymine (C>T) in rs12979860 locus of IL28B gene. If observing a one-nucleotide cytosine substitution by guanine (T>G) in rs8099917 of IL28B gene, the stable virological response is only predicted in the patients with Bα (III) blood group.
EFFECT: using invention enables the more reliable and effective prediction of the routine antiretroviral therapy.
2 tbl
